Abstract
About 180,000 American women will be diagnosed with early stage breast cancer during 1993. In many of these patients breast cancer is a systemic disease at diagnosis and thus not curable by local treatment alone. The development of optimal forms of systemic adjuvant therapy has been a major area of research for more than 30 years. The two most widely employed types of adjuvant therapy, cytotoxic chemotherapy and tamoxifen, have been shown to improve relapse-free and overall survival in certain patient subsets. This review highlights recent advances in adjuvant therapy of early stage breast cancer and discusses current treatment guidelines.
Original language | English (US) |
---|---|
Pages (from-to) | 112-116 |
Number of pages | 5 |
Journal | World journal of surgery |
Volume | 18 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 1994 |
ASJC Scopus subject areas
- Surgery